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Although functional asplenia from infarctions may be
a major contributor to increased infectious mortality
in sickle-cell disease (SCD), this relationship has not
been fully defined. We used the transgenic Berkeley
SCD mouse to define blood and splenic immunophe-
notypic differences in this model compared with
C57BL/6 and hemizygous controls. In the serum of
SCD mice, we found increased IgG2a and suppressed
IgM, IgG2b, and IgA levels. Serum IL-6 levels in SCD
mice were elevated, whereas IL-1, CXCL10, and CCL5
levels were decreased. The blood of SCD mice had
higher white blood cell counts, with an increased
percentage of lymphocytes and decreases in other
leukocytes. Immunophenotyping of lymphocytes re-
vealed higher percentages of CD8 and T-regulatory
cells and lower percentages of B cells. SCD mouse
spleens exhibited histological disorganization, with
reduction of defined lymphoid follicles and expan-
sion of red pulp, a greater than fourfold increase in
splenic mononuclear cells, marked expansion of the
nucleated red blood cell fraction, and B-cell and CD8
T-cell lymphopenia. Within the splenic B-cell popula-
tion, there was a significant decrease in B-1a B cells,
with a corresponding decrease in IgA secreting
plasma cells in the gut. Confocal microscopy of
spleens demonstrated complete disruption of the nor-
mal lymphofollicular structure in the white pulp of
SCD mice without distinct B, T, and marginal zones.
Our findings suggest that altered SCD splenic mor-phological characteristics result in an impaired sys-
temic immune response. (Am J Pathol 2012, 181:
1725–1734; http://dx.doi.org/10.1016/j.ajpath.2012.07.034)
Millions worldwide live with sickle-cell disease (SCD),
the most common inherited blood disorder that is
caused by a single point mutation in the -globin gene,
resulting in the production of abnormal red blood cell
(RBC) hemoglobin. In the deoxygenated state, hemo-
globin polymerizes to form relatively stiff filaments,
forcing RBCs to assume an irregular sickled shape.
These sickled RBCs are thought to occlude small
blood vessels, resulting in what is termed a vaso-oc-
clusive crisis. Such episodes are recurrent, spontane-
ous complications of SCD in which microvascular in-
farction leads to extreme pain and widespread organ
dysfunction. These problems often lead to several
other complications of the disease, such as anemia
and stroke; consequently, most patients with SCD live
to between the ages of 40 and 50 years.1 Surprisingly,
the most common cause of death in those with SCD is
infection, not stroke or organ failure. The life expec-
tancy of patients with SCD has increased in recent
decades because of early interventions, such as uni-
versal newborn screening for the disease, the use of
prophylactic penicillin, and the administration of vac-
cines to prevent infections.
One critical immunological organ that is affected early
in individuals with SCD is the spleen. It is a complex, but
highly organized, structure composed of white pulp, red
pulp, and the marginal zone. The red pulp is critical for
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extramedullary hematopoiesis, and the production of an-
tibodies from resident plasmablasts that migrate out of
the splenic follicles after antigen-specific differentiation.
The white pulp is organized as lymphoid sheaths with B-
and T-cell compartments. Clonal expansion of activated
B cells occurs in the B-cell follicles, leading to isotype
switching and somatic hypermutation, whereas T cells
form T-cell zones, where they interact with dendritic cells
and passing B cells. The marginal zone serves as a
transitory boundary between the red and white pulp and
contains unique sets of macrophages and B cells that
appear to be important for mounting responses against
T-cell–independent antigens, such as the capsular poly-
saccharide of invasive bacterial species.2 Intrasplenic
shunting results in reduced blood flow through the spleen
in pediatric patients with SCD, rendering them function-
ally asplenic. Repeated infarction of the spleen through-
out childhood causes severe fibrosis and calcification
and eventually results in autosplenectomy and, presum-
ably, impaired immunity. Loss of the spleen has a dra-
matic negative effect on natural IgM-producing B-1a B-
cell numbers on splenectomy in mice3 and may also have
a similar effect in homologous cells in humans.4 B-1a B
cells are imperative for protection against invasive en-
capsulated bacteria, such as Streptococcus pneu-
moniae,5 and they are essential for maintaining high lev-
els of secretory IgA in the gut.6 Much of the morbidity and
mortality associated with SCD can be attributed to dis-
eases caused by encapsulated bacteria, such as S.
pneumoniae,7 making the study of the role of the SCD
spleen in infectious disease pathogenesis imperative to
the improvement of patient health.
SCD is a human disease that is not found in other
species, making the generation of an animal model to
study the disease in detail a difficult endeavor. However,
several different transgenic mice have been developed,
including a mouse with fully humanized hemoglobin.8
The murine globin genes have been knocked out of these
mice, whereas transgenes express human hemoglobin.
These mice recapitulate several aspects of disease ob-
served in humans, including sickled erythrocytes and
histological damage to multiple organ systems. These
mice also demonstrate a pro-inflammatory state when
administered a low-dose lipopolysaccharide challenge
that produces an exaggerated inflammatory response,
with elevated levels of tumor necrosis factor-, IL-1, and
soluble vascular cell adhesion molecule-1 in the serum
and bronchoalveolar lavage fluid.9 Unfortunately, there is
a paucity of data about the immune system of these SCD
mice at baseline, which is important because this disease
in humans has many secondary, and even life-threaten-
ing, infectious complications.10
We hypothesized that altered splenic histopathological
architecture from repeated vaso-occlusive infarctions
leads to impaired systemic immunity. To our knowledge,
detailed immunophenotyping and imaging of SCDmouse
spleens have not been published. Therefore, the purpose
of this study was to assess the basic immune status of the
SCD transgenic mouse. In doing so, we have identified
blood, gut, and splenic immunophenotypic differencesthat might lead to further mechanistic explanations for
how the spleen is involved in increased morbidity and
mortality from infection in SCD.
Materials and Methods
Mice
Three groups of female mice were used: C57BL/6, trans-
genic sickle-cell mice, and hemizygous sickle-cell litter-
mates. All mice were obtained from The Jackson Labo-
ratory (Bar Harbor, ME) and were aged 8 to 12 weeks and
weighed 15 to 25 g at sacrifice. Berkeley sickle-cell trans-
genic mice [Tg(Hu-miniLCR1GAS) Hba-/- Hbb-/-]
expressing human HBA and HBBS and no longer ex-
pressing mouse Hba and Hbb were used as a murine
model of SCD. The stock background of this strain is a
mixture of FVB/N, 129, DBA/2, black Swiss, and 50%
C57BL/6 genomes. It was backcrossed to C57BL/6 one
generation after importation to The Jackson Laboratory.
Littermate controls of the Berkeley transgenic SCD
mouse (generated on the same mixed background of
strains) that express no mouse Hba, but do express one
copy of mouse Hbb, human HBA, and HBBS producing a
hemizygous, sickle cell trait–like genotype were used as
a second control arm.
All mice were housed conventionally in plastic cages
with corncob bedding. The mouse room was maintained
at 22°C to 24C with a daily light-dark cycle (light from
6 AM to 6 PM). Chow and water were supplied ad libitum.
The protocols for mice used were approved by the Ani-
mal Care Committee at the University of Connecticut
Health Center, Farmington.
Harvesting of Tissues
On humane euthanization of mice with an i.p. ketamine-
xylazine overdose, whole blood was immediately col-
lected via cardiac puncture and divided as follows: i) into
heparinized tubes for peripheral blood mononuclear cell
isolation or automated complete blood cell counts and
leukocyte differential counts (Charles River Laboratory,
Wilmington, MA); ii) into nonheparinized tubes for serum
purification; and iii) onto glass slides for peripheral blood
smears. Blood in heparinized tubes that was used for
peripheral blood mononuclear cell analysis was treated
with Tris ammonium chloride solution (nine parts 0.83%
w/v NH4Cl and one part 2.57% w/v Tris, pH 7.0) lysis at
37°C before resuspending in HBSS and before counting
via hemocytometer. The blood in nonheparinized tubes
was allowed to clot at room temperature. Samples were
then spun at 800  g in an Eppendorf centrifuge at room
temperature. Serum was pipetted off and frozen for later
use at 80°C. Peripheral blood smears were made by
smearing a small aliquot of venous blood in a single layer
onto a clean glass slide, allowing cells to air dry and
fixing with methanol for 5 minutes before May-Grunwald
staining. Spleens were harvested and placed in HBSS on
ice and then mashed with a rubber tip from a 5-mL
syringe through a cell strainer (Falcon 352340; BD Bio-
sciences, Franklin Lakes, NJ) into a 50-mL tube. After
Immunological Alterations in Murine SCD 1727
AJP November 2012, Vol. 181, No. 5rinsing with 10 mL of HBSS, mashed spleens were spun
for 5 minutes at 200  g in a Beckman TJ-6 (Beckman
Coulter, Brea, CA). The supernatant was decanted, and
the pellet was resuspended in TAC to lyse splenic RBCs.
The cellular suspension was then put through a screen,
and the tube was filled with 25 mL of HBSS and then spun
for 5 minutes at 200 g. Supernatant was then decanted.
TAC lysis of splenic cells was repeated, if necessary.
HBSS, 5 to 10 mL, was added, and the specimen was put
through the screen again. Total nucleated cell counts
from blood and spleens were obtained using a hemocy-
tometer with nigrosin dye exclusion as a measure of
viability. Aliquots containing 106 cells were resuspended in
fluorescence-activated cell sorting buffer. In addition, an
aliquot of this nucleated cell suspension was taken to de-
termine cell differentials. For histological analysis, mouse
spleens were harvested, fixed in 10% buffered formalin,
and processed using standard techniques. For confocal
microscopy, intact spleens were harvested and immersed
in optimal cutting temperature solution and frozen at80°C
until they were divided into sections. For IgA ELISpot anal-
ysis, the small intestine was extracted and fat deposits and
fecal matter were removed. Peyer’s patches were plucked
and placed in HBSS on ice and then mashed between two
microscope slides to harvest cells. Peyer’s patches cells
were washed and counted, as previously described, and
placed in RPMI 1640 medium with penicillin, streptomycin,
L-glutamine, and 5% fetal calf serum (FCS).
Antibodies
The following monoclonal antibodies were used in this
study for flow cytometry: CD3-Cy5.5 (145-2C11; BD Bio-
sciences), CD4–activated protein C (APC)–Cy7 (RM4-5;
BioLegend, San Diego, CA), CD8–fluorescein isothiocya-
nate (53-6.72; BD Biosciences), CD19-PerCP-Cy5.5
(1D3; BD Biosciences), CD19-phosphatidylethanolamine
(PE) (eBio1D3; eBioscience, San Diego, CA), CD25-PE
(PC61.5; eBioscience), B220-Pacific Blue (RA3-6B2; BD
Biosciences), B220-APC-eFluor780 (RA3-6B2; eBiosci-
ence), Foxp3-APC (FJR-16s; eBioscience), CD21-PE
(4E3; eBioscience), CD23–fluorescein isothiocyanate
(B3B4; eBioscience), CD23-PE-Cy7 (B3B4; eBiosci-
ence), CD43–fluorescein isothiocyanate (S7; BD Biosci-
ences), CD5-APC (53-7.3; eBioscience), CD11b–Alexa
Fluor 700 (M1/70; BD Biosciences), and IgM-PerCP-
Cy5.5 (R6-60.2; BD Biosciences). Corresponding isotype
controls were also obtained and used. In addition, the
following monoclonal antibodies were used for confocal
microscopy: CD8-Cy5 (53-6.7; eBioscience), B220–Al-
exa Fluor 488 (RA3-6B2; Invitrogen, Carlsbad, CA), and
MOMA-biotinylated-streptavidin 546 (MOMA1; BMA Bio-
medical, Augst, Switzerland).
Fluorescence-Activated Cell Sorting Analysis
Cell pellets containing lymphocytes from tissue prepara-
tions were resuspended in PBS solution (containing 0.2%
bovine serum albumin and 0.1% NaN3) at a concentra-
tion of 1  105 to 1  106 white blood cells/mL, and 100
L of the cells were diluted 1:1 with 100 L of the appro-priate monoclonal antibody and incubated at 4°C for 30
minutes. Foxp3 T-regulatory (Treg) cells were identified
by staining lymphocytes with anti-CD3, anti-CD4, and
anti-CD25, followed by permeabilization using fixation/
permeabilization buffer, per the manufacturer’s instruc-
tions. Cells were then stained using an anti-Foxp3 anti-
body. After staining, cells were washed twice with PBS
solution (0.2% bovine serum albumin and 0.1% NaN3),
and relative fluorescence intensities were determined us-
ing an LSR-II (Becton-Dickinson, San Diego, CA) and
analyzed with FlowJo flow cytometry analysis software
(FlowJo, Ashland, OR). Fluorescence minus one controls
were used to assist with gating.
IgA ELISpot
Anti-mouse IgA ELISpot kits were obtained from Mabtech
Inc. (Cincinnati, OH) and used per the manufacturer’s
instructions. Briefly, ELISpot plates were wet with 70%
ethanol for 2 minutes and washed three times with sterile
water. Plates were then coated with 100 L per well of 10
g/mL anti-mouse IgA antibody and incubated overnight
at room temperature. Plates were then washed three
times with PBS and blocked for 30 minutes with RPMI
1640 medium and 5% FCS at room temperature. Plates
were then washed with PBS, and 100,000, 20,000, 5000,
and 1000 Peyer’s patches cells from each mouse were
plated in duplicate and incubated overnight at 37°C and
5% CO2. Plates were then washed with PBS and incu-
bated for 2 hours with 100 L of 1 g/mL of anti-IgA biotin
antibody with 0.5% FCS. Plates were washed again with
PBS and incubated for 1 hour with 100 L of a 1:1000
dilution of streptavidin–horseradish peroxidase with 0.5%
FCS. Plates were then washed with PBS and allowed to
develop for approximately 20 minutes with 100 L of TMB
substrate. The reaction was stopped with DI water, and
spots were counted using a Fisher Scientific Micromaster
light microscope (Hampton, NY).
Light and Confocal Microscopy
Fixed spleen tissue sections were stained with H&E and
examined using light microscopy. All specimens were
evaluated with a microscope-mounted Nikon Eclipse
400TM camera (Tokyo, Japan). Digital images were gen-
erated using Spot RT SliderTM Software (Spot Imaging,
Sterling Heights, MI) and evaluated in Microsoft Photo
EditorTM (Microsoft, Redmond, WA).
Frozen spleen sections (20 m thick) were washed in
PBS and stained overnight at 4°C with anti-CD8, anti-
B220, and anti-MOMA antibodies in 2% normal goat se-
rum and 2% FCS/PBS solution. Tissues were then fixed in
2% paraformaldehyde for 2 hours at 4°C, washed,
mounted, and analyzed. Confocal images were collected
using a Zeiss (Oberkochen, Germany) LSM-510-Meta
confocal microscope mounted on an Axiovert 100M with
automated xyz control equipped with an argon laser
(emission, 458, 488, and 514 nm) and two HeNe lasers
(emission wavelengths, 543 and 633 nm). Image analysis
was performed using Imaris Suite (Bitplane, Inc., South
Windsor, CT).
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Chemokine Measurements
Frozen serum samples obtained from mice were thawed
and used for analysis. For assessment of cytokines and
chemokines, samples were processed using a Milliplex
Mouse Cytokine/Chemokine 22-plex kit (catalog
MPXMCYTO70KPMX22; Millipore, Billerica, MA) following
the manufacturer’s instructions. Assay sensitivities (min-
imum detectable concentrations) were as follows: gran-
ulocyte colony-stimulating factor (CSF; 0.9 pg/mL), GM-
CSF (5.6 pg/mL), IL-1a (5.1 pg/mL), IL-1b (2.0 pg/mL),
IL-2 (0.8 pg/mL), IL-4 (0.4 pg/mL), IL-5 (0.7 pg/mL), IL-6
(1.8 pg/mL), IL-7 (0.9 pg/mL), CXCL1 (1.4 pg/mL), IL-9
(6.0 pg/mL), IL-10 (3.3 pg/mL), IL-12 (p40) (4.9 pg/mL),
IL-12 (p70) (4.1 pg/mL), IL-13 (6.3 pg/mL), IL-15 (6.5
pg/mL), IL-17 (0.5 pg/mL), CXCL10 (0.6 pg/mL), CCL2
(5.3 pg/mL), CCL3 (8.7 pg/mL), CCL5 (2.5 pg/mL), inter-
feron- (0.9 pg/mL), and tumor necrosis factor- (1.0
pg/mL). Immunoglobulin concentrations were deter-
mined using Milliplex Mouse Immunoglobulin Isotype Kit
Panels (catalog MGAM-300; Millipore) following the man-
ufacturer’s instructions. Assay sensitivities (minimum de-
tectable concentrations) were as follows: IgM (0.3 ng/
mL), IgG1 (0.3 ng/mL), IgG3 (0.4 ng/mL), IgG2a (0.4
ng/mL), IgG2b (0.4 ng/mL), and IgA (0.7 ng/mL). Sam-
ples were analyzed using a Bio-Rad Bioplex-200 system
Figure 1. SCD mice have increased peripheral blood white blood cells (W
parameters. A–I: Automated complete blood cell (CBC) and differential bloo
mice are conducted by Charles River Laboratory. Bars represent mean  SEM levels.
multiple pairwise comparisons between groups using the Newman-Keuls post hoc(Hercules, CA), with recombinant murine cytokines as
standards, and Luminex bead array software (Austin, TX)
was used to analyze the data.
Statistics
Statistical comparisons between groups were made with
one-way analysis of variance, and multiple pairwise com-
parisons were conducted using the Newman-Keuls post
hoc test using GraphPad Prism version 5 (GraphPad
Software, San Diego, CA). All data were expressed as
mean  SEM. Differences were considered significant if
P  0.05.
Results
Peripheral Blood and Serum Analyses
An examination of the peripheral blood of C57BL/6, hem-
izygous, and SCD mice showed normal erythrocyte mor-
phological characteristics in the wild-type mice. The
hemizygous mice demonstrated increased target-
shaped RBCs and no evidence of sickled erythrocytes.
The SCD peripheral blood showed marked anisopoikilo-
cytosis, including characteristic sickled cells. As shown
in Figure 1, there was a significant increase in the con-
centration of white blood cells (WBCs; Figure 1A, P 
nd an altered distribution of leukocytes, as well as anemic hematological
ounts from C57BL/6 (n  5), hemizygous (Hemi; n  7), and SCD (n  3)BCs) a
d cell cSignificant differences are determined by one-way analysis of variance with
test. *P  0.05, **P  0.01, and ***P  0.001.
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(Figure 1E, P  0.01) and basophils (Figure 1F: P 
0.001 compared with C57BL/6 and P  0.05 compared
with hemizygous mice) in the SCD mice when compared
with both hemizygous and C57BL/6 mice. Lymphocytes
were increased in the SCD mice relative to the other
groups. Hemizygous mice also had a higher percentage
of lymphocytes when compared with C57BL/6 mice (Fig-
ure 1C, P  0.01 for comparisons with SCD mice, and
P  0.05 for comparison between C57BL/6 and hemizy-
gous mice). The proportion of monocytes (Figure 1B, P
0.05) was reduced in both hemizygous and SCD mice
compared with C57BL/6 mice, and there was also a sig-
nificant reduction in the proportion of neutrophils when
C57BL/6 and SCD mice were compared (Figure 1D, P 
0.05). No difference in platelet counts was observed, but
reduced hemoglobin and hematocrit were found in the
SCD mice when compared with hemizygous and
C57BL/6 mice (Figure 1, H and I, P  0.001 for hemo-
globin and hematocrit), as previously described.8,11
Hemizygous mice were also anemic when compared with
C57BL/6 mice, but less so than SCD mice (P  0.01 for
hemoglobin and P  0.05 for hematocrit).
The serum immunoglobulin isotype analysis of SCD
mice demonstrated suppressed IgM (135,472  19,985
ng/mL) (Figure 2A, P  0.01), IgA (6556  815 ng/mL)
(Figure 2B, P  0.001), and IgG2b (165,667  49,217
ng/mL) (Figure 2D, P  0.01) levels when compared with
C57BL/6 mice (IgM, 358,295  60,412 ng/mL; IgA,
19,568  2437 ng/mL; and IgG2b, 410,023  67,005
ng/mL). However, serum IgG2a levels were significantly
higher in SCD mice (482,597  151,900 ng/mL) com-
pared with C57BL/6 mice (18,034  3296 ng/mL) (Figure
2C, P  0.01). Overall, hemizygous mice demonstrated
serum immunoglobulin levels (IgM, 140,386  13,558
ng/mL; IgA, 8432  868 ng/mL; and IgG2b, 126,693 
14,641 ng/mL) similar to those of SCD mice, with the
exception of IgG2a (356,602  81,491 ng/mL), which
had a significantly lower level in hemizygous compared
with SCD mice (P  0.05), raising the possibility of an
Figure 2. SCD and hemizygous mice have decreased serum IgG2b, IgM, and
IgA levels, but increased IgG2a production. A–D: Serum immunoglobulins
from C57BL/6 (n  11), hemizygous (Hemi; n  11), and SCD (n  9) mice
are analyzed via Luminex bead assay. Bars represent mean  SEM levels.
Significant differences are determined by one-way analysis of variance with
multiple pairwise comparisons between groups using the Newman-Keuls
post hoc test. *P  0.05, **P  0.01, and ***P  0.001.effect from mouse strain background. No significant dif-
ferences in serum IgG1 and IgG3 levels were observed
(data not shown).
Of 17 serum cytokines that were measured, IL-1 (Fig-
ure 3A) and IL-6 (Figure 3B) were significantly different
between SCD and control mice. The mean serum IL-1
levels were higher in C57BL/6 mice (894  303 pg/mL)
compared with SCD mice (86  19 pg/mL) (P  0.05).
There was no significant difference in serum IL-1 level
between hemizygous and C57BL/6 or SCD mice. The
mean serum IL-6 level was significantly higher in SCD
mice (15  4 pg/mL) compared with both C57BL/6 mice
(3 0.5 pg/mL) (P 0.01) and hemizygous controls (4
0.6 pg/mL) (P 0.001). There was no difference in serum
cytokine expression of granulocyte CSF, GM-CSF, inter-
feron-, IL-1b, IL-2, IL-4, IL-5, IL-7, IL-9, IL-10, IL-12,
IL-13, IL-15, IL-17, and tumor necrosis factor- (data not
shown).
We measured five serum chemokines in SCD and con-
trol mice. Two chemokines (CXCL10 and CCL5) were
significantly lower in the SCD mice (Figure 4). The mean
serum CXCL10 levels (Figure 4A) were lower in SCDmice
(55  9 pg/mL) than in C57BL/6 mice (119  15 pg/mL)
(P  0.001). There was no difference in serum CXCL10
levels between hemizygous and C57BL/6 or SCD mice.
SCD mice had significantly lower serum CCL5 levels
(20  3 pg/mL) than C57BL/6 and hemizygous mice
(36  5 and 38  4, respectively) (P  0.05). There were
no differences in serum chemokine levels of CXCL1,
CCL2, or CCL3 (data not shown).
To assess whether variations in lymphocyte subpopu-
lations could account for the observed differences in
Figure 3. SCD mice have elevated serum IL-6 and decreased IL-1a cytokine
expression. A and B: C57BL/6 (n  11), hemizygous (Hemi; n  11), and
SCD (n  9) mice undergo serum cytokine analysis via Luminex bead assay.
Bars represent mean  SEM levels. Significant differences are determined by
one-way analysis of variance with multiple pairwise comparisons between
groups using the Newman-Keuls post hoc test. *P  0.05, **P  0.01, and
***P  0.001.
Figure 4. SCD mice have decreased CXCL10 and CCL5 chemokine expres-
sion. A and B: C57BL/6 (n 11), hemizygous (Hemi; n 11), and SCD (n
9) mice undergo serum chemokine analysis via Luminex bead assay. Bars
represent mean  SEM levels. Significant differences are determined by
one-way analysis of variance with multiple pairwise comparisons between
groups using the Newman-Keuls post hoc test. *P  0.05, **P  0.01.
riance w
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mice, lymphocyte flow cytometric analysis was under-
taken on peripheral blood. Overall, SCD mice had a
higher percentage of CD3 (T) cells in their blood com-
pared with both C57BL/6 and hemizygous mice (Figure
5A: 30%, 16%, and 17%, respectively; P  0.001). More
specifically, SCDmice demonstrated higher percentages
of peripheral blood T cells (and a decrease in the per-
centage of peripheral blood B cells; Figure 5A, P 
0.001). There was no difference in blood percentage
CD3CD4 (CD4) cells among the three groups (P 
0.172). However, SCD mice demonstrated a significantly
higher percentage of circulating CD4CD25FoxP3
Treg cells than both C57BL/6 (P 0.01) and hemizygous
(P  0.05) control mice (Figure 5C: 5%, 3%, and 3%,
respectively). The percentage of CD3CD8 (CD8)
cells in the blood of SCD mice was higher (46%) than in
the blood of hemizygous (39%; P  0.01) and C57BL/6
(35%; P  0.001) mice. SCD and hemizygous mice had
a lower percentage of B220CD19 cells (B cells) than
SCD mice (9%, 9%, and 27%, respectively; P  0.001).
Spleen
Gross and Histological Pathological Characteristics
On gross pathological analysis, SCD mice had greater
than sixfold larger spleens (Figure 6, A and B; P  0.001)
compared with C57BL/6 and hemizygous mice. Murine
C57BL/6 spleens, similar to human spleens, have highly
organized areas of red and white pulp. Histologically,
C57BL/6 mouse spleens had normal splenic organization
(Figure 6C), with clearly identifiable regions of red and
white pulp. Spleens from hemizygous mice also had nor-
mal histological characteristics (data not shown). How-
ever, SCD mouse spleens exhibited marked histological
disorganization (Figure 6D). Most notable were the re-
duction of clearly defined splenic white pulp (including
few lymphoid follicles) and expanded red pulp.
Cellular Analysis
To elucidate the effect of SCD splenic histopathologi-
cal distortion at the cellular level, we analyzed the mono-
Figure 5. SCD mice have decreased circulating B cells and increased circula
analysis on peripheral blood of C57BL/6 (n  6), hemizygous (n  6), and S
anti-CD3, anti-CD4, anti-CD25, anti-FoxP3, anti-CD8, anti-CD19, and anti-B2
CD4 T cells are CD3CD4 lymphocytes. CD8 T cells are CD3CD8 lym
percentages. Significant differences are determined by one-way analysis of va
post hoc test. *P  0.05, **P  0.01, and ***P  0.001.nuclear cell content of the SCD spleens compared withwild-type. Not surprisingly, total splenic mononuclear
cells were significantly increased in SCD spleens by 4.5-
fold (Figure 7A, P  0.001), approximately the same
order of magnitude of difference in weight. However, the
distribution of mononuclear cells accounting for the in-
crease in total count was dissimilar. Nucleated RBCs
accounted for most of the total cellular increase in the
SCD spleens (40% in SCD mouse spleens and 2% in
control mouse spleens; P  0.001) (Figure 7B). This
marked increase of nucleated RBCs likely accounted for
the relative lymphopenia in SCD spleens (37% in SCD
spleens and approximately 90% in control mouse
spleens; P  0.001) (Figure 7B). Both T- and B-cell sub-
sets of SCD spleens were statistically decreased com-
pared with control groups (P  0.001) (Figure 7C). Re-
ductions in both T and B cells were also observed in
hemizygous mice when compared with C57BL/6 mice
(P  0.01 and P  0.001, respectively), albeit less so
than was observed with the SCD mice. Although the
percentage of CD4 T cells was no different between the
8 T cells and Tregs in peripheral blood. A–C: Lymphocyte flow cytometric
5) mice is performed. Single-cell suspensions are isolated and stained with
odies. T cells are CD3 lymphocytes. B cells are B220CD19 lymphocytes.
s. Tregs are CD4CD25FoxP3 lymphocytes. Bars represent mean  SEM
ith multiple pairwise comparisons between groups using the Newman-Keuls
Figure 6. The SCD mouse spleen is grossly enlarged and has distorted
histological organization. SCD spleens are six times larger by wet weight than
hemizygous and C57BL/6 spleens (A), which is evident on gross examination
(B). Histologically, on standard H&E staining at an original magnification
of 4, SCD splenic tissue has a markedly distorted organization (D) com-
pared with C57BL/6 mice (C), which have organized areas of white pulp and
red pulp. Significant differences are determined by one-way analysis ofting CD
CD (n 
20 antib
phocytevariance with multiple pairwise comparisons between groups using the
Newman-Keuls post hoc test. ***P  0.001.
are dete
.01, and
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0.3), the percentage of CD8 T cells was statistically
decreased in both SCD and hemizygous mice when
compared with C57BL/6 mice (Figure 7D, P  0.01).
Most striking was the 80% reduction of splenic B-1a B
cells in SCD mice compared with both control groups
(Figure 7E, P 0.01). This change was associated with a
marked reduction of IgA-secreting plasma cells in the
Peyer’s patches of the small intestine of the SCD mice
when compared with C57BL/6 mice (Figure 7F, P 
0.05).
Confocal Microscopy
To determine immune cellular localization and com-
partmental distribution in the splenic tissue, confocal mi-
croscopy was used. Sections of splenic tissue from
C57BL/6 (data not shown), hemizygous, and SCD mice
were stained to isolate the B220 B-cell, CD8 T-cell,
and MOMA marginal zones (Figure 8). Normal follicular
architecture of the white pulp, consisting of centralized T
cells, surrounding B cells, and marginal zone macro-
phages, was observed in the C57BL/6 and hemizygous
mice. However, complete disruption of the normal lym-
phofollicular structure was found in the white pulp of SCD
mice, and lymphoid aggregates that could be found were
sparse and much smaller than those of hemizygous or
C57BL/6 mice.
Discussion
We have identified altered splenic morphological char-
acteristics that may account for our observed aberrant
Figure 7. SCD mice have 4.5-fold more total mononuclear cells, a marked in
A–F: Groups of C57BL/6 (n  5), hemizygous (Hemi; n  6), and SCD (n 
isolated from the spleens and stained with May-Grünwald stain. Total num
individual proportion of mononuclear cells (both leukocytes and nucleated
cytometry. Bars represent mean  SEM percentages. Significant differences
between groups using the Newman-Keuls post hoc test. *P  0.05, **P  0serum immunoglobulin, cytokine, and chemokine levels.Taken together, these local splenic anatomical distortions
may account for impaired pathogen recognition and pro-
cessing, thereby leading to high rates of infectious com-
plications in this disease. Humans living with SCD are
highly susceptible to severe infections.12 Recent evi-
dence suggests that such events may be related to dys-
regulated immunity associated with suppression of sev-
eral immune parameters (eg, antibody responses) and
increased baseline inflammation. The reasons for im-
mune dysregulation in these patients are not clear, but
the dogma has been that repeated infarction with subse-
quent atrophy and dysfunction of the spleen is the key
mediator of this phenomenon. Indeed, patients with SCD
often have splenic dysfunction beginning in the early
months of life, which can contribute to impaired immunity
to pathogenic insults, such as invasion by encapsulated
bacteria.13 The SCD mouse spleens described herein
were grossly enlarged and exhibited severely disrupted
microarchitecture when compared with controls. Histo-
logical and confocal microscopy images of the spleens of
SCD mice showed a dramatically attenuated white pulp
in which no discernable T-cell zone could be identified.
Not surprisingly then, reduced percentages of both B
and T cells were observed in this tissue, as determined
by flow cytometry. Such changes in lymphocyte proportions
and possibly function could have a profound effect on
adaptive immune responses. Fortunately, most childhood
vaccinations are administered before major changes in the
spleen occur, allowing for antigen-specific memory cells to
be generated.14
Interestingly, natural IgM-producing B-1a B cells,
which have been essential for combating some of the
pathogens of high significance for SCD, do not appear to
in nucleated RBC content, and significantly altered lymphocyte distributions.
e are euthanized and their spleens are removed. Single-cell suspensions are
ononuclear cells in the spleens are determined by a hemocytometer. The
is determined by a manual differential. Lymphocytes are identified by flow




RBCs)be maintained in the spleens of SCD mice. Given that
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may not help abrogate the loss of this important cell type.
Furthermore, splenic B-1a B cells appear to have a direct
link to natural IgA-secreting plasma cells in the gut, which
are imperative for protection against many pathogens of
the gastrointestinal tract. Indeed, individuals with SCD
appear to be more prone to invasive infection with Sal-
monella species,15 opening the possibility that the in-
creased susceptibility to infection may, in fact, be asso-
ciated with changes in the spleen and the subsequent
loss of B-1a and IgA-secreting plasma B cells.
In addition to the disruption in lymphocyte populations
in the white pulp of the spleen, the marginal zone was not
distinct in the SCD mice by confocal microscopy. Proper
function of these cells in the marginal zone is imperative
for defense against encapsulated bacteria.16,17 The lack
of an organized splenic marginal zone around lymphoid
follicles may explain why patients with SCD are highly
susceptible to such infections. Not only will such altera-
tions in these cells likely affect antigen presentation and
immunity associated with the integrity of the marginal
zone, but loss of macrophages from this region can also
negatively affect the removal of atypical erythrocytes
from the circulation,18 possibly resulting in enlargement
or sequestration of the spleen. Taken together, the aber-
rant splenic structure observed in SCD mice appears to
closely mimic changes found in human patients and
likely contributes to immune dysregulation observed in
this disease.In addition to localized immune dysregulation in the
SCD spleen, patients also display aberrant immune phe-
notypes in peripheral blood,19,20 and this trend held true
for the SCD mice used in this study. Immunophenotyping
of lymphocytes in the SCD mice indicated that the per-
centage of B cells was drastically reduced, with a con-
comitant increase in T cells (driven by a predominant
increase in T-regulatory and CD8 cells). This shift is in
contrast to several reports of lymphocyte immunopheno-
typic profiling in patients with SCD, showing an increase
in the number of B cells with a reduction in T cells.21,22
The increase in B-cell number in patients with SCD does
not result in a corresponding increase in antibodies; in
fact, these patients exhibit reduced antibody and lym-
phoproliferative responses to stimuli. There was a signif-
icant reduction in serum IgM, IgA, and IgG2b antibodies
in SCD mice, which may be explained by the observed
reduction in circulating B cells and the disorganization of
the splenic white pulp. The white pulp is critical for clonal
expansion, isotype switching, and somatic hypermutation
of activated B cells. However, serum IgG2a levels were
much higher in SCD mice, which is in stark contrast to the
other antibodies. The reasons for this increase and the
mechanism by which it happens are not evident from this
work; therefore, it is imperative to elucidate the role IgG2a
in SCD to ensure that these antibodies are not patholog-
ical. Regardless of the differences in lymphocyte profiles
between patients with SCD and SCD mice, both exhibit
Figure 8. The cellular architecture of SCD
splenic follicles is abnormal. Spleen sections are
fixed and stained with B220 (Alexa Fluor 488)
for B cells, CD8 (Cy 5) for CD8 T cells, and
MOMA (Alexa Fluor 546) for metallophilic mac-
rophages. MZ, marginal zone where the MOMA-
positive macrophages should be resident. B-cell
follicles (B), T-cell zones (T), and MOMA-posi-
tive macrophages are not as distinct in the SCD
mice compared with the hemizygous mice, as
shown in B and D. Original magnification: 10
(A and C); 20 (B and D). The follicles are
sparser in the SCD mice compared with the
hemizygous controls, as seen in A and C.striking changes that likely affect adaptive immunity,
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cination in this disease.
Lymphocyte function is heavily dependent on the cy-
tokine milieu present in the circulation and tissues, and
slight changes can have profound effects on their phe-
notype and proliferation. Measurements of serum cyto-
kines demonstrated reduced concentrations of CXCL10
and IL-1 in SCD mice when compared with C57BL/6
mice. Several functions can be ascribed to these cyto-
kines, but both can have an effect on the function of T
cells, indicating that SCD mice may have altered re-
sponses to presented antigens.23 Perhaps more impor-
tant, SCD mice had a reduced level of CCL5 when com-
pared with both hemizygous and C57BL/6 mice. This
chemokine is important for the chemotaxis of several
leukocytes, including T cells. CCL5 also appears to reg-
ulate CD8 antiviral responses,24 indicating that these
mice may have a deficiency in cell-mediated immunity.
Whether there are reductions in these three cytokines in
patients with SCD has not been determined, but if such
changes are conserved in the human model, then this
may explain why patients with SCD are particularly prone
to severe viral infections, such as parvovirus B19 and
pandemic H1N1 influenza A.25,26 In addition to the re-
duced CXCL10, IL-1, and CCL5 concentrations in SCD
mice, these animals also have increased levels of IL-6
when compared with hemizygous littermates and con-
trols. This cytokine can be pro- or anti-inflammatory,
depending on several factors, and has been found at
increased levels in splenectomized patients with thala-
ssemia.27 Our results are in stark contrast to those re-
ported by Holtzclaw et al,9 which indicated that these
mice do not have an elevated IL-6 level at baseline mea-
surements. The differences in our results may be the
result of the different methods used to measure IL-6 (they
used enzyme-linked immunosorbent assay, whereas we
used Luminex). Furthermore, there is debate in the liter-
ature about the levels of serum IL-6 in patients with SCD,
because some groups have observed no difference
when compared with controls,19,28 whereas others have
determined that there is an increase in patients with
SCD.29-31 These discrepancies may be attributed to the
different ages of the patients tested (and the subsequent
different stages of splenic atrophy), but our results are in
line with the group that observed increased serum IL-6
concentrations in SCD. Taken together, SCD mice ap-
pear to have a cytokine skew that may contribute to
immune dysregulation and may help explain the weak
immunity observed clinically in patients with SCD.
Herein, we have reported several immune parameters
that are aberrant in SCD mice (and, in some cases, in
their hemizygous littermates). Some of these changes
have been observed in their human counterparts, some
are different, and others have not been studied in hu-
mans at all. Even when differences between the SCD
mice and humans were noted, the overall functional phe-
notype appears to be conserved (ie, reduced antibody
responses in both, even though B-cell numbers tend to
increase in patients with SCD but decrease in SCD mice).
Altogether, these findings support the contention that
SCD is a state of altered (and perhaps impaired) immu-nity, which is exemplified by the finding of a reduced
percentage of splenic B-1a B cells and gut IgA-secreting
B cells in SCD mice. Furthermore, SCD mice also appear
to live with heightened inflammation, as was demon-
strated by the high levels of serum IL-6. The finding that
hemizygous mice also have altered immune responses at
baseline is intriguing and requires further investigation.
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